Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide

Schizophrenia Research

Volumn 59, Issue 1, 2003, Pages 59-66

  Potkin, Steven G ^a   Anand, Ravi ^b   Alphs, Larry ^b   Fleming, Kirsten ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Mortality; Neurocognition; Schizoaffective; Schizophrenia; Suicide

Indexed keywords

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TASK PERFORMANCE;

ADULT; CANADA; COGNITION DISORDERS; FEMALE; GREAT BRITAIN; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS, NONPARAMETRIC; SUICIDE; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 0037209841     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00159-7     Document Type: Article

References (36)

1. Addington D., Addington J., Maticka-Tindale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry. 163:1998;S39-S44.
2. Amador S.F., Strauss D.H., Yale S.A., Flaum M., Endicott J., Gorman J.M. Assessment of insight in psychosis. Am. J. Psychiatry. 150:1993;873-879.
3. Amador X.F., Friedman J.H., Kasapis C., Yale S.A., Flaum M., Gorman J.M. Suicidal behavior in schizophrenia and its relationship to awareness of illness. Am. J. Psychiatry. 153:1996;1185-1188.
4. Arango V., Underwood M.D., Mann J.J. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann. N. Y. Acad. Sci. 836:1997;269-287.
5. Beck A.T., Kovacs M., Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J. Consult. Clin. Psychol. 2:1979;343-352.
6. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry. 157:2000;549-559.
7. Black D.W., Fisher R. Mortality in DSM-IIIR schizophrenia. Schizophr. Res. 7(2):1992;109-116.
8. Bleuler M. The Schizophrenic Disorders: Long-Term Patient and Family Studies. 1978;Yale Univ. Press, New Haven. Translated by S.M. Clemens.
9. Breier A., Astrachan B.M. Characterization of schizophrenic patients who commit suicide. Am. J. Psychiatry. 141:1984;206-209.
10. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
11. Caldwell C.B., Gottesman I.I. Schizophrenia: a high-risk factor for suicide: clues to risk reduction. Suicide Life-Threat. Behav. 22:1992;479-493.
12. Carpenter W.T., Buchanan R.W. Domains of Psychopathology Relevant to the Study of Etiology and Treatment of Schizophrenia. Schizophrenia: Scientific Progress. 1989;13-22 Oxford Univ. Press, New York.
13. Cohen S., Leonard C.V., Farberow N.L., Shneidman E.S. Tranquilizers and suicide in schizophrenic patients. Arch. Gen. Psychiatry. 11:1964;312-317.
14. Cohen S., Lavelle J., Rch C.L., Bromet E. Rates and correlates of suicide attempts in first-admission psychotic patients. Acta Psychiatr. Scand. 90:1994;167-171.
15. Collins A.A., Remington G.J., Coulter K., Birkett K. Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophr. Res. 27:1997;37-44.
16. Fleming K., Thyrum P.T., Jin Y., Potkin S.G. The neurocognitive effects of Seroquel "quetiapine": a preliminary study. J. Clin. Psychopharmacol. 21(5):2001;527-529.
17. Goldberg T.E., Greenberg R.D., Griffin S.J. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48.
18. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
19. Heila H., Isometsa E.T., Henriksson M.M., Heikkinen M.E. Suicide in schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am. J. Psychiatry. 154:1997;1235-1242.
20. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
21. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry. 169:1996;444-450.
22. Lindenmayer J.P., Bernstein-Hyman R., Grochowki S. A new five factor model of schizophrenia. Psychiatr. Q. 65:1994;299-322.
23. Lindenmayer J.P., Czobor P., Alphs L., Anand R., Islam Z., Pestreich L. InterSePT Publications Group The InterSePT Scale for Suicidal Thinking (ISST) reliability and validity. Schizophr. Res. 49:2001;5.
24. Lipman R.S. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol. Bull. 18:1982;69-77.
25. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 21:1999;99S-105S.
26. Meltzer H.Y. Suicide and schizophrenia: clozapine and the InterSePT study. International clozaril/leponex suicide prevention trial. J. Clin. Psychol. 60:1999;47-50. Suppl.
27. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry. 152:1995;183-190.
28. Miles C.P. Conditions predisposing to suicide: a review. J. Nerv. Ment. Dis. 164:1977;231-245.
29. Mortensen P.B., Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiatry. 163:1993;183-189.
30. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry. 36:1991;239-245.
31. Potkin S.G., Fleming K., Jin Y., Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol. 21(5):2001;479-483.
32. Rennie T.A.C. Follow-up study of five hundred patients with schizophrenia admitted to the hospital from 1913 to 1923. Arch. Neurol. Psychiatry. 32:1939;877-891.
33. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M.et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry. 48:1991;618-624.
34. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. Mortality in current and former users of clozapine. Epidemiology. 6:1997;671-677.
35. Warnes H. Suicide in schizophrenics. Dis. Nerv. Syst. 29(Suppl. 5):1968;35-40.
36. Westermeyer J.F., Harrow M., Marengo J.T. Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J. Nerv. Ment. Dis. 179:1991;259-266.